N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64% Market Closed
Market Cap: 107.5m EUR

NeuBase Therapeutics Inc
Selling, General & Administrative

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeuBase Therapeutics Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Selling, General & Administrative
-$9.1m
CAGR 3-Years
3%
CAGR 5-Years
-20%
CAGR 10-Years
-16%
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
2%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.8B
CAGR 3-Years
-3%
CAGR 5-Years
-5%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7B
CAGR 3-Years
-10%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$3.2B
CAGR 3-Years
-17%
CAGR 5-Years
-15%
CAGR 10-Years
-16%
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
107.5m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available
N

See Also

What is NeuBase Therapeutics Inc's Selling, General & Administrative?
Selling, General & Administrative
-9.1m USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Selling, General & Administrative amounts to -9.1m USD.

What is NeuBase Therapeutics Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-16%

Over the last year, the Selling, General & Administrative growth was 23%. The average annual Selling, General & Administrative growth rates for NeuBase Therapeutics Inc have been 3% over the past three years , -20% over the past five years , and -16% over the past ten years .

Back to Top